Preventing respiratory syncytial virus (RSV) disease in children

Science. 2021 May 14;372(6543):686-687. doi: 10.1126/science.abf9571.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / immunology
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Female
  • Humans
  • Immunity, Active
  • Immunity, Maternally-Acquired*
  • Immunization, Passive*
  • Immunoglobulins, Intravenous / therapeutic use
  • Infant
  • Pregnancy
  • Respiratory Syncytial Virus Infections / immunology
  • Respiratory Syncytial Virus Infections / prevention & control*
  • Respiratory Syncytial Virus Vaccines* / administration & dosage
  • Respiratory Syncytial Virus Vaccines* / adverse effects
  • Respiratory Syncytial Virus Vaccines* / immunology
  • Respiratory Syncytial Viruses / immunology*
  • Respiratory Tract Infections / immunology
  • Respiratory Tract Infections / prevention & control*
  • Respiratory Tract Infections / virology
  • Viral Fusion Proteins / immunology

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • F protein, human respiratory syncytial virus
  • Immunoglobulins, Intravenous
  • Respiratory Syncytial Virus Vaccines
  • Viral Fusion Proteins
  • respiratory syncytial virus immune globulin intravenous